Stephen Nava
Corporate Officer/Principal presso Regulator Affairs Quality Assurance Consulting Services, Inc.
Posizioni attive di Stephen Nava
Società | Posizione | Inizio | Fine |
---|---|---|---|
Regulator Affairs Quality Assurance Consulting Services, Inc. | Corporate Officer/Principal | 01/01/2004 | - |
Storia della carriera di Stephen Nava
Precedenti posizioni note di Stephen Nava
Società | Posizione | Inizio | Fine |
---|---|---|---|
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Consigliere Generale | 01/01/2005 | 01/06/2011 |
Acumen Sciences LLC | Consigliere Generale | 01/01/2002 | 01/01/2004 |
VIRACTA THERAPEUTICS, INC. | Responsabile della Conformità | 09/07/2018 | - |
Consigliere Generale | 09/07/2018 | - |
Formazione di Stephen Nava
Texas A&M University-Kingsville | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Posizioni
General Counsel | 3 |
Compliance Officer | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
Acumen Sciences LLC | |
Regulator Affairs Quality Assurance Consulting Services, Inc. |
- Borsa valori
- Insiders
- Stephen Nava
- Esperienza